

PE/Cyanine7 Anti-Human HLA-DR Antibody[L243]

Catalog Number: E-AB-F1111H

Note: Centrifuge before opening to ensure complete recovery of vial contents.

Description

Reactivity	Human
Host	Mouse
Isotype	Mouse IgG2a, κ
Clone No.	L243
Isotype Control	PE/Cyanine7 Mouse IgG2a, κ Isotype Control[C1.18.4] [Product E-AB-F09802H]
Conjugation	PE/Cyanine 7
Conjugation Information	PE/Cyanine7 is designed to be excited by the Blue (488 nm), Green (532 nm) and yellow-green (561 nm) lasers and detected using an optical filter centered near 775 nm (e.g., a 780/60 nm bandpass filter).
Storage Buffer	Phosphate buffered solution, pH 7.2, containing 0.09% sodium azide and 1% BSA.


Applications

Recommended usage

FCM

Each lot of this antibody is quality control tested by flow cytometric analysis. **The amount of the reagent is suggested to be used 5 μL of antibody per test (million cells in 100 μL staining volume or per 100 μL of whole blood).** Please check your vial before the experiment. Since applications vary, the appropriate dilutions must be determined for individual use.

Data



Human peripheral blood lymphocytes are stained with PE/Cyanine7 Anti-Human HLA-DR Antibody (filled gray histogram). Unstained lymphocytes (empty black histogram) are used as control.

Preparation & Storage

Storage	Keep as concentrated solution. This product can be stored at 2-8°C for 12 months. Please protected from prolonged exposure to light and do not freeze.
Shipping	Ice bag

Antigen Information

Alternate Names	DRA/DRB1;HLA class II histocompatibility antigen DR alpha/ DRB1-15 beta chain;HLA-DRA1/DRB1;MHC class II antigen DRA
Uniprot ID	P01903;P01911

For Research Use Only

Gene ID

3122,3123

Background

HLA-DR is a heterodimeric cell surface glycoprotein comprised of a 36 kD α (heavy) chain and a 27 kD β (light) chain. It is expressed on B cells, activated T cells, monocytes/macrophages, dendritic cells, and other non-professional APCs. In conjunction with the CD3/TCR complex and CD4 molecules, HLA-DR is critical for efficient peptide presentation to CD4+ T cells.